Filip Janku Sells 11,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $20.22, for a total value of $239,505.90. Following the transaction, the insider directly owned 59,992 shares in the company, valued at approximately $1,213,038.24. The trade was a 16.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Filip Janku also recently made the following trade(s):

• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total value of $642,600.00.

Monte Rosa Therapeutics Trading Up 2.9%

Monte Rosa Therapeutics stock opened at $22.28 on Friday. The firm has a 50 day moving average of $18.96 and a 200 day moving average of $18.63. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of -15.05 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 12-month low of $4.12 and a 12-month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The firm had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. On average, analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GLUE shares. JPMorgan Chase & Co. lifted their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Guggenheim cut their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Wells Fargo & Company dropped their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Monte Rosa Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.50.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC purchased a new position in Monte Rosa Therapeutics during the fourth quarter valued at $30,000. Nisa Investment Advisors LLC lifted its stake in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Monte Rosa Therapeutics during the 4th quarter valued at about $63,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Monte Rosa Therapeutics during the 3rd quarter valued at about $32,000. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.